Skip to main content

CORRECTION article

Front. Pharmacol., 11 January 2023
Sec. Drugs Outcomes Research and Policies
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1123542

Corrigendum: Formulation and development of transferrin targeted solid lipid nanoparticles for breast cancer therapy

This article is a correction to:

  1. Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy

    1. Read original article
Geeta S. BhagwatGeeta S. Bhagwat1Rajani B. Athawale Rajani B. Athawale2*Rajeev P. GudeRajeev P. Gude3Shadab MdShadab Md4Nabil A. AlhakamyNabil A. Alhakamy4Usama A. FahmyUsama A. Fahmy4Prashant Kesharwani Prashant Kesharwani5*
  • 1H. K. College of Pharmacy, Mumbai, India
  • 2Prin. K. M. Kundanani College of Pharmacy, Mumbai, India
  • 3Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India
  • 4Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
  • 5Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

A Corrigendum on
Formulation and development of transferrin targeted solid lipid nanoparticles for breast cancer therapy

by Bhagwat G, Athawale RB, Gude RP, Md S, Alhakamy N, Fahmy U and Kesharwani P (2020). Front. Pharmacol. 11:614290. doi: 10.3389/fphar.2020.614290

In the published article, there was an error in Figure 1 as published. The figure erroneously contained two duplicate images. The corrected Figure 1 and its caption appear below.

FIGURE 1
www.frontiersin.org

FIGURE 1. Qualitative cell uptake of developed SLN formulations by confocal microscopy.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: breast cancer, cancer, solid lipid nanoparticles, tamoxifen, targeted drug delivery

Citation: Bhagwat GS, Athawale RB, Gude RP, Md S, Alhakamy NA, Fahmy UA and Kesharwani P (2023) Corrigendum: Formulation and development of transferrin targeted solid lipid nanoparticles for breast cancer therapy. Front. Pharmacol. 13:1123542. doi: 10.3389/fphar.2022.1123542

Received: 14 December 2022; Accepted: 30 December 2022;
Published: 11 January 2023.

Edited and reviewed by:

Kaisar Raza, Central University of Rajasthan, India

Copyright © 2023 Bhagwat, Athawale, Gude, Md, Alhakamy, Fahmy and Kesharwani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Prashant Kesharwani, prashantdops@gmail.com; Rajani B. Athawale, rajaniathawale2020@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.